Audited financial results of the company for the quarter and financial year ended 31.03.2026.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bal Pharma reported standalone revenue of Rs 31,079.70 lakhs for FY2026, up 2.7% from Rs 30,249.64 lakhs in FY2025. However, net profit declined 13.4% to Rs 675.12 lakhs from Rs 779.95 lakhs in the prior year. On a consolidated basis, revenue grew 2.8% to Rs 31,166.13 lakhs while net profit fell 12.7% to Rs 632.00 lakhs. The company declared a dividend of Rs 1.20 per share (12% on face value Rs 10). EBITDA margin expanded marginally from 5.05% to 5.57%. The Board also approved a preferential issue of 10 lakh warrants to promoters and a new employee stock option plan with 5 lakh options. Statutory auditors issued an unmodified opinion, indicating no material concerns in the financial statements.
The stock may see neutral to slightly negative reaction as profit declined despite modest revenue growth, though the dividend and promoter warrant issuance signal management confidence. The unmodified audit opinion provides assurance on financial quality.